Govt Amends NDCT Rules to Cut Drug Approval Timelines

30 Jan 2026 CW Team

The Union Ministry of Health and Family Welfare has recently notified key amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019, aimed at reducing regulatory burden and improving Ease of Doing Business in the pharmaceutical sector. The changes focus on simplifying approval processes and significantly shortening timelines for drug development and clinical research.

Under the revised framework, the requirement for pharmaceutical companies to obtain a test licence from the Central Drugs Standard Control Organization (CDSCO) for non-commercial manufacture of small quantities of drugs for research or analysis has been replaced with a prior-intimation system. Companies may now proceed after submitting an online intimation, except for a limited category of high-risk drugs such as cytotoxic, narcotic and psychotropic substances. This move is expected to save at least 90 days in the drug development cycle.

For categories where test licences continue to apply, the statutory processing timeline has been reduced from 90 days to 45 days. With CDSCO handling nearly 30,000–35,000 such applications annually, the reform is expected to substantially ease compliance requirements for the industry.

In another major change, prior approval for certain low-risk Bioavailability and Bioequivalence (BA/BE) studies has been waived. These studies can now commence based on a simple online intimation, benefiting the generic pharmaceutical segment. CDSCO processes around 4,000–4,500 BA/BE applications each year.

Dedicated online modules on the National Single Window System and the SUGAM portal will support seamless implementation. Overall, the reforms are expected to accelerate research, optimise regulatory resources, and strengthen India’s position as a global hub for pharmaceutical R&D.

Real Estate

02 Feb 2026

Union Budge: Infra-Led Urban Shift

The Union Budget FY27 reinforces infrastructure-led urbanisation as the backbone of India’s real estate and housing growth. Higher public capital expenditure, City Economic Regions, risk-mitigation mechanisms and REIT-led asset monetisation are being widely viewed as long-term enablers, even as the industry continues to seek sharper supply-side reforms and affordability-focused measures. Here are a few industry insights:Dr Niranjan Hiranandani, Chairman, NAREDCO & Hiranandani Group“The Union Budget 2026-27 is growth-oriented and stability-focused, supporting consumption and aiming to s..

Budget 2026 Charts Path for Infrastructure-Led, Tech-Driven Growth

The Union Budget 2026–27 signals strong continuity in India’s macroeconomic strategy, anchored in elevated public capital expenditure, fiscal discipline, and a sharper focus on manufacturing, infrastructure, and regional development. With capital outlay pegged at ₹12.2 lakh crore and a fiscal deficit target of around 4.3 per cent, the Budget balances growth ambition with stability, offering long-term visibility to investors and project developers.A dominant theme is the centrality of infrastructure as a multiplier for economic expansion. Public capex now accounts for over 3.3 per cent of..

Tata Power Arm Crosses 10 GW EPC Milestone

Tata Power Renewable Energy Ltd (TPREL) has achieved a major milestone by executing 10 gigawatts of engineering, procurement and construction (EPC) renewable energy projects to date, reinforcing its position in India’s clean energy infrastructure sector. According to the company, the executed portfolio comprises 4.2 gigawatts of in-house projects and 5.8 gigawatts of third-party projects. Of the total 10 gigawatts commissioned so far, 9.7 gigawatts are solar projects and 290 megawatts are wind projects. In the first nine months of FY26, TPREL commissioned 1.88 gigawatts of EPC renewable en..